Q-omics provides the consensus-scored LINC01006 profile across patient tissues and cancer cell-line models. LINC01006 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01006 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, LINC01006 RNA expression shows 16,843 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRP, and THYM as cancer lineages where LINC01006 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01006 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01006 survival associations across molecular data types. LINC01006 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01006 RNA expression–survival associations across cancer types. High LINC01006 expression shows unfavorable associations in KIRP, BLCA, ESCA and LIHC, but favorable associations in UVM and CESC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01006 RNA expression.
This table summarizes LINC01006 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01006. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01006 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRP, LIHC, LUAD and COAD. The KIRP box plot shows higher LINC01006 RNA expression in tumor versus normal tissue (log2 FC = +0.793, t-test p = .001).
This table shows molecular features associated with LINC01006 in patient tissues and cancer cell lines. In patient samples, LINC01006 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
